Abstract:Therapeutic Advances in Musculoskeletal Disease, Volume 14, Issue , January-December 2022. Gout is characterized by monosodium urate (MSU) crystal deposits in and within joints. These deposits result from persistent hyperuricaemia and most typically lead to recurrent acute inflammatory episodes (gout flares). Even though some aspects of gout are well characterized, uncertainties remain; this upcoming decade should provide further insights into many of these uncertainties. Synovial fluid analysis allows for the identification of MSU crystals and unequivocal diagnosis. Non-invasive methods for diagnosis are being explored, such as Raman spectroscopy and imaging modalities. Both ultrasound and dual-energy computed tomography (DECT) allow the detection of MSU crystals; this not only provides a mean of diagnosis, but also has furthered gout knowledge defining the presence of a preclinical deposition in asymptomatic hyperuricaemia. Scientific consensus establishes the beginning of gout as the beginning of symptoms (usually the first flare), but the concept is currently under review. For effective long-term gout management, the main goal is to promote crystal dissolution treatment by reducing serum urate below 6 mg/dL (or 5 mg/dL if faster crystal dissolution is required). Current urate-lowering therapies' (ULTs) options are limited, with allopurinol and febuxostat being widely available, and probenecid, benzbromarone, and pegloticase available in some regions. New xanthine oxidase inhibitors and, especially, uricosurics inhibiting urate transporter URAT1 are under development; it is probable that the new decade will see a welcomed increase in the gout therapeutic armamentarium. Cardiovascular and renal comorbidities are common in gout patients. Studies determining whether optimal treatment of gout will positively impact these comorbidities are currently lacking, but will hopefully be forthcoming. Overall, the single change that will most impact gout management is greater uptake of international rheumatology society recommendations. Innovative strategies, such as nurse-led interventions based on these recommendations have recently demonstrated treatment success for people with gout.

Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors

Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of gout and its risk factor, 1990 to 2050

Epidemiology of gout – Global burden of disease research from 1990 to 2019 and future trend predictions

Physiology of Hyperuricemia and Urate-Lowering Treatments

Gout: state of the art after a decade of developments

[Gout, beyond the joint: How should we treat it?]

A Review of Uric Acid, Crystal Deposition Disease, and Gout

Global, Regional, and National Prevalence of Gout From 1990 to 2019: Age-Period-Cohort Analysis With Future Burden Prediction

Changing paradigms in the management of gout

Environmental Triggers of Hyperuricemia and Gout

Role of diet in hyperuricemia and gout

Burden of gout among different WHO regions, 1990–2019: estimates from the global burden of disease study

Pathophysiology and Treatment of Gout Arthritis; including Gout Arthritis of Hip Joint: A Literature Review

A glance into the future of gout

Recent developments in diet and gout

Environmental factors and risk of gout

Global status and trends in gout research from 2012 to 2021: a bibliometric and visual analysis

Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options

A perspective on diet and gout

Moving the Needle in Gout Management: The Role of Culture, Diet, Genetics, and Personalized Patient Care Practices

Trends in healthcare utilization by patients with gout: A cross-sectional study using Health Insurance Review and Assessment Service data